ZA9010332B - Method of reducing or preventing adverse effect of steroid therapy and compositions therefor - Google Patents

Method of reducing or preventing adverse effect of steroid therapy and compositions therefor

Info

Publication number
ZA9010332B
ZA9010332B ZA9010332A ZA9010332A ZA9010332B ZA 9010332 B ZA9010332 B ZA 9010332B ZA 9010332 A ZA9010332 A ZA 9010332A ZA 9010332 A ZA9010332 A ZA 9010332A ZA 9010332 B ZA9010332 B ZA 9010332B
Authority
ZA
South Africa
Prior art keywords
reducing
adverse effect
steroid therapy
preventing adverse
compositions therefor
Prior art date
Application number
ZA9010332A
Other languages
English (en)
Inventor
Ronald Lee Goldberg
Lee Goldberg Ronald
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA9010332B publication Critical patent/ZA9010332B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA9010332A 1989-12-22 1990-12-12 Method of reducing or preventing adverse effect of steroid therapy and compositions therefor ZA9010332B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45521589A 1989-12-22 1989-12-22

Publications (1)

Publication Number Publication Date
ZA9010332B true ZA9010332B (en) 1991-08-28

Family

ID=23807878

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9010332A ZA9010332B (en) 1989-12-22 1990-12-12 Method of reducing or preventing adverse effect of steroid therapy and compositions therefor

Country Status (14)

Country Link
EP (1) EP0434625B1 (xx)
JP (1) JP2934023B2 (xx)
KR (1) KR100191381B1 (xx)
AT (1) ATE121296T1 (xx)
AU (1) AU641966B2 (xx)
CA (1) CA2032859C (xx)
DE (1) DE69018799T2 (xx)
DK (1) DK0434625T3 (xx)
ES (1) ES2071080T3 (xx)
GR (1) GR3015900T3 (xx)
IE (1) IE67510B1 (xx)
IL (1) IL96711A (xx)
NZ (1) NZ236614A (xx)
ZA (1) ZA9010332B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW267102B (xx) 1992-03-13 1996-01-01 Ciba Geigy
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
AU3545795A (en) * 1994-09-08 1996-03-27 Chiron Corporation A method of improved production of insulin-like growth factor
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1997015319A1 (en) * 1995-10-23 1997-05-01 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
ZA978334B (en) * 1996-09-16 1999-03-16 Univ Dalhousie Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
WO1999051262A2 (en) 1998-04-03 1999-10-14 Chiron Corporation Use of igfi for treating articular cartilage disorders
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
US8119591B2 (en) 2005-08-01 2012-02-21 Genera Istrazivanja D.O.O. Methods and compositions for regenerating articular cartilage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003409A1 (en) * 1986-11-14 1988-05-19 Institute Of Molecular Biology, Inc. Wound healing and bone regeneration
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β

Also Published As

Publication number Publication date
KR910011279A (ko) 1991-08-07
CA2032859C (en) 2007-09-17
EP0434625A3 (en) 1991-10-02
NZ236614A (en) 1993-10-26
KR100191381B1 (ko) 1999-06-15
DE69018799D1 (de) 1995-05-24
JP2934023B2 (ja) 1999-08-16
EP0434625A2 (en) 1991-06-26
AU641966B2 (en) 1993-10-07
IL96711A (en) 1996-01-19
DK0434625T3 (da) 1995-06-26
IL96711A0 (en) 1991-09-16
GR3015900T3 (en) 1995-07-31
JPH04210648A (ja) 1992-07-31
EP0434625B1 (en) 1995-04-19
ATE121296T1 (de) 1995-05-15
AU6824790A (en) 1991-06-27
IE904684A1 (en) 1991-07-17
CA2032859A1 (en) 1991-06-23
DE69018799T2 (de) 1995-09-21
IE67510B1 (en) 1996-04-03
ES2071080T3 (es) 1995-06-16

Similar Documents

Publication Publication Date Title
ZA9010332B (en) Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
AU6853290A (en) Composition and method for the treatment of osteoporosis in mammals
GR3032844T3 (en) Prevention and treatment of peripheral neuropathy.
ZA945249B (en) Parathyrold hormone and raloxifene for increasing bone mass
CA2030518A1 (en) Osteoinductive compositions
IL101229A0 (en) Compositions for accelerated wound healing
AU4861493A (en) Clear leave-on treatment composition and method
EP0607278A4 (en) PROCESS FOR IMPROVING INTESTINAL ABSORPTION.
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
AU1888692A (en) Composition and method for treating tumors
IL102344A0 (en) Method of preventing and treating chemotherapy-induced alopecia
EP0457848A4 (en) Treatment of pulmonary dysfunction and ventilator dependency with growth hormone
AU3720293A (en) Method and compositions for treating acne
AU2434992A (en) Methods and compositions for treating sunburns
AU5889794A (en) Method and compositions for treating anoestrus
MX9408106A (es) Metodo y composicion para el tratamiento de hepatitis autoinmune.